Fig. 1
From: The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer
Loss of WAVE3 expression or its phosphorylation sensitize TNBC cells to chemotherapeutics. Parental MDA-MB-231 (A–C) or 4T1 (D–F) cells (GFP), their WAVE3-deficient derivatives (W3-KO), or the W3-KO expressing either wildtype (W3-WT) or phospho-mutant (W3-Y4) WAVE3 were treated with increased concentrations of cisplatin (A and D), paclitaxel (B and E) or doxorubicin (C and F) for 2 days followed by MTT assay to determine cell viability. Data are the mean ± SD (n = 3, *p < 0.05; **p < 0.01, Student’s t test). Data shown is representative of three independent experiments